Online appendix (Figures)
|
|
- Bruce Newton
- 5 years ago
- Views:
Transcription
1 July 211 August 211 September 211 October 211 November 211 December 211 January 212 February 212 March 212 April 212 May 212 June 212 July 212 August 212 September 212 October 212 November 212 December 212 January 213 February 213 October 213 Proportion of pharmaceutical concerns Pharmacy Practice 216 Jul-Sep;14(3):786 online appendix. doi: /PharmPract suppl Online appendix (Figures) 5,, 4,5, 4,, of thyroid hormones of L-thyroxine 3,5, 3,, 15. of phenprocoumon of methiamazole 2,5, 2,, 1,5, 1 concerns with thyroid hormones concerns with L-thyroxine 1,, 5, 5. concerns with phenprocoumon concerns with methiamazole Figure a). where exchange for a product under rebate contract would have been those prescriptions (right y-axis) for drugs with a narrow therapeutic index or variable bioavailability between July 211 and. (eissn: ISSN: X) 1
2 July 211 August 211 September 211 October 211 November 211 December 211 January 212 February 212 March 212 April 212 May 212 June 212 July 212 August 212 September 212 October 212 November 212 December 212 January 213 February 213 October 213 Proportion of pharmaceutical concerns Pharmacy Practice 216 Jul-Sep;14(3):786 online appendix. doi: /PharmPract suppl 5, , 14. 4, 35, 3, 25, 2, 15, 1, of estradiol TTS of fentanyl TTS of buprenorphine TTS concerns with estradiol TTS concerns with fentanyl TTS concerns with buprenorphine TTS 5, 2. Figure b). where exchange for a product under rebate contract would have been those prescriptions (right y-axis) for drugs with the dosage form transdermal therapeutic system (TTS) between July 211 and. (eissn: ISSN: X) 2
3 July 211 August 211 September 211 October 211 November 211 December 211 January 212 February 212 March 212 April 212 May 212 June 212 July 212 August 212 September 212 October 212 November 212 December 212 January 213 February 213 October 213 Percentage of pharmaceutical concerns Pharmacy Practice 216 Jul-Sep;14(3):786 online appendix. doi: /PharmPract suppl 5, , 14. 4, 35, 3, 25, 2, 15, 1, 5, of methotrexate (parenteral use) of beclometasone (for inhalation) of lorazepam of ondansetron concerns with methotrexate (parenteral use) concerns with beclometasone (for inhalation) concerns with lorazepam concerns with ondansetron Figure c). where exchange for a product under rebate contract would have been those prescriptions (right y-axis) for methotrexate for parenteral use, beclomethasone for inhalation, lorazepam and ondansetron between July 211 and. (eissn: ISSN: X) 3
4 July 211 August 211 September 211 October 211 November 211 December 211 January 212 February 212 March 212 April 212 May 212 June 212 July 212 August 212 September 212 October 212 November 212 December 212 January 213 February 213 October 213 Proportion of pharmaceutical concerns Pharmacy Practice 216 Jul-Sep;14(3):786 online appendix. doi: /PharmPract suppl 2, 1 18, 9. 16, 8. 14, 7. 12, 1, 8, 6, 4, of cefixime of cefpodoxime concerns with cefixime concerns with cefpodoxime 2, 1. Figure d). where exchange for a product under rebate contract would have been those prescriptions (right y-axis) for drugs with different package sizes between the prescribed (and dispensed) products (cephalosporin antibiotics) and the products listed in rebate contracts between July 211 and. (eissn: ISSN: X) 4
5 July 211 August 211 September 211 October 211 November 211 December 211 January 212 February 212 March 212 April 212 May 212 June 212 July 212 August 212 September 212 October 212 November 212 December 212 January 213 February 213 October 213 Percentace pharmaceutical concerns Pharmacy Practice 216 Jul-Sep;14(3):786 online appendix. doi: /PharmPract suppl 5, , 4, 1 of hydromorphone of morphine 35, 8. of olanzapine 3, 25, 2, 15, 1, 5, of levodopa + decarboxylase inhibit. concerns with hydromorphone concerns with morphine concerns with olanzapine concerns with levodopa + decarboxylase inhibit. Figure e). where exchange for a product under rebate contract would have been those prescriptions (right y-axis) for drugs intended to treat severe disease states (e.g., schizophrenia, severe pain, Parkinson disease) between July 211 and. (eissn: ISSN: X) 5
USE OF OPIODS AT HIGHER DOSES IN PERSONS WITHOUT CANCER: MORPHINE EQUIVALENT DOSE EDIT
BACKGROUND: USE OF OPIODS AT HIGHER DOSES IN PERSONS WITHOUT CANCER: MORPHINE EQUIVALENT DOSE EDIT Approximately 10% of patients who are prescribed opioids and seek care from multiple doctors, are prescribed
More informationNATL. II. Health Net Approved Indications and Usage Guidelines: Diagnosis of cancer AND. Member is on fentanyl transdermal patches AND
Coverage of drugs is first determined by the member s pharmacy or medical benefit. Please consult with or refer to the Evidence of Coverage document I. FDA Approved Indications: The management of breakthrough
More informationGENERIC MEDICINES (Non-Innovator Brand) PRESCRIBING POLICY
GENERIC MEDICINES (Non-Innovator Brand) PRESCRIBING POLICY First issued by/date Issue Version Purpose of Issue/Description of Change Planned Review Date August 2018 1.0 Promoting generic prescribing whenever
More informationCDC Guideline for Prescribing Opioids for Chronic Pain
National Center for Injury Prevention and Control CDC Guideline for Prescribing Opioids for Chronic Pain John Halpin, MD, MPH Medical Officer Division of Unintentional Injury Prevention Prescription Drug
More informationProposed Changes to Existing Measure for HEDIS : Use of Opioids at High Dosage (UOD)
Proposed Changes to Existing Measure for HEDIS 1 2020: Use of Opioids at High Dosage (UOD) NCQA seeks comments on proposed revisions to the Use of Opioids at High Dosage HEDIS measure. The current measure
More informationA National Perspective on the Abuse and Diversion of Prescription Drugs
A National Perspective on the Abuse and Diversion of Prescription Drugs Hilary L. Surratt, Ph.D Steven P. Kurtz, Ph.D. ARSH: Center for Applied Research on Substance Use and Health Disparities Faculty
More informationAssessment of prior opioid tolerance among new users of fentanyl transdermal system in FDA s Sentinel System
Assessment of prior opioid tolerance among new users of fentanyl transdermal system in FDA s Sentinel System Noelle Cocoros, Marc Larochelle, Jennifer Popovic, Andrew Petrone, Cynthia Kornegay, Jing Ju,
More informationThe Latest Prescription Trends for Controlled Prescription Drugs
The Latest Prescription Trends for Controlled Prescription Drugs September 1, 2015 Christopher M. Jones PharmD, MPH Senior Advisor Office of Public Health Strategy and Analysis Office of the Commissioner
More informationDuragesic patch. Duragesic patch (fentanyl patch) Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.31 Subject: Duragesic patch Page: 1 of 6 Last Review Date: March 18, 2016 Duragesic patch Description Duragesic patch (fentanyl
More informationAppendix 3: Taking controlled and prescription drugs to other countries
Appendix 3: Taking controlled and prescription drugs to other countries Some patients receiving palliative care travel to other countries and they will need to take their medicines with them. Practitioners
More informationOpioids in the Community: Chronic pain, Palliative Care, and Addiction. Dr Ahmed Jakda September 2017
Opioids in the Community: Chronic pain, Palliative Care, and Addiction Dr Ahmed Jakda September 2017 Outline Context Background Action Delisting Highstrength Long- Acting Opioids Opioid use and prescribing
More information1/29/2013. Schedule II Controlled Substances: Basics and Beyond. Controlled Substances. Controlled Substances, Schedule I
chedule II Controlled ubstances: Basics and Beyond James L. Besier, Ph.D., R.Ph., FAHP Adjunct Associate Professor College of Nursing Adjunct Assistant Professor James L. Winkle College of Pharmacy University
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Transmucosal Immediate Release Fentanyl Products Reference Number: CP.CPA.211 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Transmucosal Immediate Release Fentanyl Products Reference Number: CP.HNMC.211 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important
More informationClinical Policy: Opioid Analgesics Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid
Clinical Policy: Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationPRESCRIPTION DRUG MONITORING PROGRAM ST. CHARLES COUNTY Q1 2018
PRESCRIPTION DRUG MONITORING PROGRAM ST. CHARLES COUNTY Q1 2018 Contents Executive Summary... 2 User Registration & System Utilization... 4 Dispensation Rates... 6 Dispensation Rates by Geography... 6
More informationAlgorithms for Symptom Management. In End of Life Care
Algorithms for Symptom Management In End of Life Care The Use of Drugs Beyond Licence (off label) -The Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK regulates the activity of the
More informationPRESCRIPTION DRUG MONITORING PROGRAM
PRESCRIPTION DRUG MONITORING PROGRAM ST. LOUIS COUNTY Q2 2017 Contents Executive Summary... 2 User Registration & System Utilization... 4 Dispensation Rates... 6 Dispensation Rates by Geography... 6 Dispensation
More informationLimitations of use: Subsys may be dispensed only to patients enrolled in the TIRF REMS Access program (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.21 Subject: Subsys Page: 1 of 5 Last Review Date March 17, 2017 Subsys Description Subsys (fentanyl
More informationAn Evaluation of the DoD Transdermal Fentanyl Pharmacy Edit. LTC Stacia Spridgen, MSC, USA Director, DoD Pharmacoeconomic Center
An Evaluation of the DoD Transdermal Fentanyl Pharmacy Edit LTC Stacia Spridgen, MSC, USA Director, DoD Pharmacoeconomic Center 1 TRICARE Eligible Beneficiaries Monthly Average, FY08 Retirees & Family
More informationManaging Narcotics on Workers Comp Claims. Presented By: Craig S. Stern, PharmD, MBA President Pro Pharma Pharmaceutical Consultants, Inc.
Managing Narcotics on Workers Comp Claims Presented By: Craig S. Stern, PharmD, MBA President Pro Pharma Pharmaceutical Consultants, Inc. October 21, 2014 Outline Rationale Scope list drug list Recommended
More informationBree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT
Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup Opioid Prescribing Metrics - DRAFT Definitions: Days Supply: The total of all opioid prescriptions dispensed during the calendar quarter
More informationHospice High Dollar Medications and Possible Alternatives
Hospice High Dollar Medications and Possible Alternatives Ly M. Dang, PharmD LDang@HospicePharmacySolutions.com Director of Pharmacy Operations Hospice Pharmacy Solutions Topics of Discussion Hospice Coverage
More informationLong Term Care Formulary HCD - 08
1 of 5 PREAMBLE Opioids are an important component of the pharmaceutical armamentarium for management of chronic pain. The superiority of analgesic effect of one narcotic over another is not generally
More informationURGENT: Important Safety Information
July 2018 URGENT: Important Safety Information Subject: Notice of New Special Handling Instructions due to Potential for Cracked Needle Hubs and Particulate in Multiple Carpuject Luer Lock Glass Products-Corrected
More informationMedicines Optimisation Strategy
Clinical Reducing Dosing Errors with Opioid Medicines (Controlled Drug SOP): Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 20 February 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 20 February 2008 DUROGESIC 12 micrograms/hour (2.1 mg/5.25 cm²), transdermal patch Box of 5 sachets (CIP: 369 851-5)
More information1. Carrying Personal Medications into Thailand A. Medications containing narcotic drugs of category 2
Guidance for Travellers to Thailand under Treatment Carrying Personal Medications Containing Narcotic Drugs/Psychotropic Substances into/out of Thailand This guidance issued by the Narcotics Control Division,
More informationIntroduction to Pharmacology
Introduction to Pharmacology 1 Definitions Drug: It is any chemical that affect living processes. It modifies an already existing function, and does not create a new function. 2 Pharmacology: Definitions
More informationSCG1 Evaluation of High Risk Pain Medications for MME
2018 SCG Health QCDR Measure Specifications 1 SCG1 Evaluation of High Risk Pain Medications for MME Percentage of patients aged 18 years and older prescribed and actively taking one or more high risk pain
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 4000-3 Program Opioid Overutilization Cumulative Drug Utilization Review Criteria Medication Includes all salt forms, single and
More informationOxymorphone (Opana ) is indicated for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate.
Page 1 of 7 Policies Repository Policy Title Policy Number Schedule II Prior Authorization FS.CLIN.16 Application of Pharmacy Policy is determined by benefits and contracts. Benefits may vary based on
More informationOxycodone dosage for cats Chest xray to rule out TB icd10 code AI horinam jabe emesis ICD Disawar ka number kya hai Indaba zamabhebhana Sitemap
Oxycodone dosage for cats Chest xray to rule out TB icd10 code AI horinam jabe emesis ICD Disawar ka number kya hai Indaba zamabhebhana Sitemap 11-7-2017 Continued. Never change or stop taking any opioid
More informationFENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA
FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAMES: HICL = H3AT Fentanyl citrate transmucosal Actiq (fentanyl citrate) lozenge on a handle 200, 400, 600, 800,
More information2017 Alberta Triplicate Prescription Program Atlas
Prescription Program Atlas The Prescription Program (TPP) was established in 1986 to monitor the use of certain medications prone to misuse and abuse. The mandate of the TPP is: To monitor prescribing,
More informationAbout the PCTB Examination Assisting the Pharmacist in Serving Patients p. 1 Filling the Medication Order p. 3 Receiving the Medication Order p.
Preface p. ix About the PCTB Examination p. xii Assisting the Pharmacist in Serving Patients p. 1 Filling the Medication Order p. 3 Receiving the Medication Order p. 4 The Retail Medication Order p. 6
More informationMedicines Q&As Q&A Which medicines should be considered for brand-name prescribing in primary care?
Medicines Q&As Q&A 247.2 Which medicines should be considered for brandname in primary care? Prepared by UK Medicines Information (UKMi) pharmacists for NHS healthcare professionals Before using this Q&A,
More informationDME MAC Jurisdiction B Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2019 through 03/31/2019
G0333 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.048 J0285 INJECTION, AMPHOTERICIN B 50 MG $31.668 J0287 INJECTION,
More informationDME MAC Jurisdiction C Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2018 through 03/31/2018
G0333 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.068 J0285 INJECTION, AMPHOTERICIN B 50 MG $32.987 J0287 INJECTION,
More information9/5/2011. Outline. 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A
Prescription Drug Abuse Crises Outline 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A 1 1970s 1980s 2 The 1990s OXYCODONE Oxycodone/APAP OxyContin
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Opioid Analgesics Reference Number: HIM.PA.139 Effective Date: 12.01.17 Last Review Date: 11.17 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the
More informationFollow-up to Previous Reviews. Multiple Dosage Forms of Aripiprazole Prescribed Concomitantly
15 October 2015 1 Follow-up to Previous Reviews Multiple Dosage Forms of Aripiprazole Prescribed Concomitantly 2 Multiple Dosage Forms of Aripiprazole Prescribed Concomitantly Usual maximum FDA approved
More informationHistory Note: Authority G.S ; ; ; Eff. May 1, 1997; Amended Eff. January 1, 2015; March 1, 2013.
21 NCAC 46.1412 PHYSICAL REQUIREMENTS A health care facility pharmacy shall have sufficient floor space allocated to it to ensure that drugs are prepared in sanitary, well lighted, and enclosed places.
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE September 4, 2015 SUBJECT EFFECTIVE DATE September 9, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Analgesics, Narcotic Long Acting and Analgesics, Narcotic Short
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL III INDUSTRY Industrial affairs III: Consumer goods industries Pharmaceuticals and Cosmetics
EUROPEAN COMMISSION DIRECTORATE-GENERAL III INDUSTRY Industrial affairs III: Consumer goods industries Pharmaceuticals and Cosmetics Community Basic Format for Manufacturing Authorisation Explanatory Notes
More informationCaprelsa. Caprelsa (vandetanib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.16 Subject: Caprelsa Page: 1 of 5 Last Review Date: June 22, 2018 Caprelsa Description Caprelsa (vandetanib)
More informationFDB FOOD AND DRUGS BOARD G H A N A GUIDELINES FOR CONDUCTING BIOEQUIVALENCE STUDIES
FDB FOOD AND DRUGS BOARD G H A N A GUIDELINES FOR CONDUCTING BIOEQUIVALENCE STUDIES 1 SCOPE In pursuance of section 47 of the Food and Drugs Law 1992, P.N.D.C.L 305B, as amended by Act 523, 1996, these
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: HIM.PA.139 Effective Date: 12.01.17 Last Review Date: 02.18 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this policy
More informationSuboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.32 Subject: Suboxone Drug Class Page: 1 of 7 Last Review Date: June 24, 2016 Suboxone Drug Class Description
More informationOxyContin in the 90 days prior to it being discontinued.
Appendix 1 (as supplied by the authors): Supplementary data Provincial Drug Insurance program formulary listing status for OxyNeo by province Province Listing of OxyNeo BC Listed for patients covered by
More informationFighting the Good Fight: How to Convert Opioids Just Right!
Fighting the Good Fight: How to Convert Opioids Just Right! Tanya J. Uritsky, PharmD, BCPS, CPE Clinical Pharmacy Specialist - Pain Medication Stewardship Hospital of the University of Pennsylvania - Philadelphia,
More informationPrescribing Examples: Basics
Prescribing Examples: Basics 7 0 Pregabolin 5 50mg 05.. 5 6 7 8 9 5 6 5 5 5 5 50 50 50 50 75 75 RF RF RF RF RF RF 5 5 5 5 50 50 50 PJ TF PJ PJ TF TF TF 50 75 75 75 75 TF A: REGULAR PRERIPTION SHEET 5 6
More informationDose equivalent of fentanyl patch to oxycontin
Dose equivalent of fentanyl patch to oxycontin 10-3-2018 Detailed dosage guidelines and administration information for OxyContin (oxycodone hydrochloride). Includes dose adjustments, warnings and precautions.
More informationNHS WALES PRIMARY CARE PRESCRIBING ANALYSIS FOR TRAMADOL DATA TO SEPTEMBER 2014
NHS WALES PRIMARY CARE PRESCRIBING ANALYSIS FOR TRAMADOL DATA TO SEPTEMBER 2014 March 2015 This report has been prepared by the Welsh Analytical Prescribing Support Unit (WAPSU), part of the All Wales
More informationPhysician Injectable Drug List (PIDL) Department for Medicaid Services, HP, and Magellan Rx Management June 1, 2010
Physician Injectable Drug List (PIDL) Department for Medicaid Services, HP, and Magellan Rx Management June 1, 2010 Physician-Administered Drugs Physician-administered drugs are drugs, other than vaccines,
More informationCommittee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Topic: fentanyl-containing medications: - Actiq, fentanyl citrate oral transmucosal lozenges - Abstral fentanyl sublingual tablets - Fentora, fentanyl buccal tablet - fentanyl
More informationIntroducing Pharmacokinetics and Pharmacodynamics. Janice Davies Pharmacist Room 23 Maudland Building
Introducing Pharmacokinetics and Pharmacodynamics Janice Davies Pharmacist Room 23 Maudland Building JADavies5@uclan.ac.uk 1 elearn 2 DVD Any problems / questions? 3 Learning outcomes Define and discuss
More informationCalgary Long Term Care Formulary. Pharmacy & Therapeutics. February 2015
Calgary Long Term Care Formulary Pharmacy & Therapeutics February 2015 Highlights http://www.albertahealthservices.ca/4070.aspx 1 Contents February 2016... 3 Added Product(s)... 3 Not Listed, Delisted
More informationExecutive Summary. Classes Under Review: Analysis:
Outcome Report on MHQAC Edits Classes Under Review: Analysis: Atypical Antipsychotics, SSRIs, SNRIs, Antianxietals, Hypnotics, and Drugs to Treat ADD/ADHD Utilization and Cost Trends: Pre and Post Implementation
More informationARKANSAS DEPARTMENT OF HEALTH
Thank you for taking an interest in the Arkansas Prescription Monitoring Program (PMP). The goal of the PMP is to enhance patient care by ensuring the legitimate use of controlled substances. The following
More informationOregon s PDMP: An epidemiological assist tool
Oregon s PDMP: An epidemiological assist tool Todd Beran Center for Prevention and Health Promotion Oregon Health Authority PDMP TTAC Webinar February 13, 2013 1 Acknowledgements Lisa Millet, MSH, Section
More informationAppendix 1. University of Minnesota Amplatz Children s Hospital Opioid Weaning Guideline
Appendix 1. University of Minnesota Amplatz Children s Hospital Opioid Weaning Guideline 1. Pharmacist to order Narcotic Withdrawal Scores QH X 4 hours, then per table below: Narcotic Withdrawal Score
More informationINTRODUCTION. Dr Laith M Abbas Al-Huseini M.B.Ch.B, M.Sc., M.Res., Ph.D. epartment of Pharmacology and Therapeutics
INTRODUCTION Dr Laith M Abbas Al-Huseini M.B.Ch.B, M.Sc., M.Res., Ph.D. epartment of Pharmacology and Therapeutics Let s learn PHARMACOLOGY Greek Word Pharmacon Logos Drug Science Science of drugs- dealing
More informationAnalgesics: Management of Pain In the Elderly Handout Package
Analgesics: Management of Pain In the Elderly Handout Package Analgesics: Management of Pain in the Elderly Each patient or resident and their pain problem is unique. A complete assessment should be performed
More informationOpioids, Extended Release (ER) Quantity Limit Criteria Program Summary
Opioids, Extended Release (ER) Quantity Limit Criteria Program Summary This program applies to Commercial, GenPlus, NetResults A series, Netresults F series and Health Insurance Marketplace. Belbuca is
More informationMorphine equivalent calculator suboxone
Morphine equivalent calculator suboxone Gogamz Menu Best Way To Lose 30 Pounds In 6 Months Fat Burner Waist Belt Fat Burn And Target Heart Rate how much weight would i lose calculator Fastest Fat Burner
More informationHigh Risk Medicines Prescribing Policy. July 2017
High Risk Medicines Prescribing Policy July 2017 Responsible Committee: Quality Committee Date Effective: July 2017 Author: Rahinatu Amadu Supersedes: July 2016 Next Review Due: July 2018 1. INTRODUCTION
More informationMEDICINES PROMOTION AND RATIONAL USE : The Spanish Experience JOSE LUIS DOPICO
MEDICINES PROMOTION AND RATIONAL USE : The Spanish Experience JOSE LUIS DOPICO LEGAL FRAMEWORK General Health Act (1986): Established a National Health System in Spain in accordance with the following
More informationPrior Authorization Guideline
Guideline GL-35952 Opioid Quantity Limit Overrides Formulary OptumRx Formulary Note: Approval Date 7/10/2017 Revision Date 7/10/2017 Technician Note: P&T Approval Date: 2/16/2010; P&T Revision Date: 7/12/2011
More information1/26/2016. These are my own thoughts! Safe Workplace Safe Workforce Proven benefits of Stay At Work / Return To Work Process (SAW/RTW)
Dr. Paul A. Farnan farnan@mail.ubc.ca HealthQuest Occupational Health Corporation Alliance Medical Monitoring I have no financial interests or affiliation with any pharmaceutical industry or manufacturer
More informationPolicy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04
Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Date issued Issue 1 Nov 2018 Planned review Nov 2021 PPT-PGN 18 part of NTW(C)38 Pharmaceutical
More informationGeographic variations in prescription opioid dispensations and deaths among women and men in British Columbia, Canada
Geographic variations in prescription opioid dispensations and deaths among women and men in British Columbia, Canada Emilie J. Gladstone, Kate Smolina, Deirdre Weymann, Kimberly Rutherford, and Steven
More informationHarold Rogers Prescription Drug Monitoring Program Regional Meeting-Charleston, SC April 29, 2014 Andrew Holt, PharmD
Harold Rogers Prescription Drug Monitoring Program Regional Meeting-Charleston, SC April 29, 2014 Andrew Holt, PharmD National Epidemic Highlighted numerous studies/media reports State Epidemic Highlighted
More informationSynthroid oral to iv conversion
Synthroid oral to iv conversion The Borg System is 100 % Synthroid oral to iv conversion Synthroid official prescribing information for healthcare professionals. Includes: indications, dosage, adverse
More informationSurveillance of Apparent Opioid Overdoses in New Brunswick
Surveillance of Apparent Opioid Overdoses in New Brunswick 7- Quarter 4 April, 8 Surveillance of apparent opioid overdoses in New Brunswick, 7 Q4 Page of Surveillance of Apparent Opioid Overdoses in New
More informationClinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.18
Clinical Policy: Reference Number: CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory
More informationEverything You Ever Wanted to Know About the NAPLEX DONALD A GODWIN, PHD INTERIM DEAN UNM COLLEGE OF PHARMACY
Everything You Ever Wanted to Know About the NAPLEX DONALD A GODWIN, PHD INTERIM DEAN UNM COLLEGE OF PHARMACY Objectives AT THE COMPLETION OF THIS ACTIVITY, THE PHARMACIST PARTICIPANT WILL BE ABLE TO:
More informationEverything You Ever Wanted to Know About the NAPLEX DONALD A GODWIN, PHD INTERIM DEAN UNM COLLEGE OF PHARMACY
Everything You Ever Wanted to Know About the NAPLEX DONALD A GODWIN, PHD INTERIM DEAN UNM COLLEGE OF PHARMACY Objectives AT THE COMPLETION OF THIS ACTIVITY, THE PHARMACIST PARTICIPANT WILL BE ABLE TO:
More informationCLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics
Reference Number: AZ.CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid- AHCCCS Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 3053-9 Program Step Therapy Long Acting Opioids Medication Includes both brand and generic versions of the listed products unless
More informationVIRGINIA DEPARTMENT OF HEALTH OFFICE OF THE CHIEF MEDICAL EXAMINER
VIRGINIA DEPARTMENT OF HEALTH OFFICE OF THE CHIEF MEDICAL EXAMINER To promote and protect the health of all Virginians Fatal Drug Overdose Quarterly Report Edition 216.3 Publication Date: January 217 METHODS,
More informationPharmacy Management Drug Policy
SUBJECT: Opioid Management Health and Safety Program POLICY NUMBER: PHARMACY-34 EFFECTIVE DATE: 6/2007 LAST REVIEW DATE: 07/01/2018 If the member s subscriber contract excludes coverage for a specific
More informationEnd Stage Liver Disease Regional Audit Casenote Survey
1. This questionnaire is an audit of clinical documentation of patients who have died of end stage liver disease. If you have any questions about how this form should be completed please contact Dr Grace
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 3053-7 Program Step Therapy Long Acting Opioids Medication Includes both brand and generic versions of the listed products unless
More informationBC Coroners Service Prescription Opiate-Related Overdose Deaths
This report summarises prescription opiate-related overdose deaths reported to the BC Coroners Service between 2005 and 2010 with a classification of accidental, suicide, or undetermined. Cases were included
More informationHOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain
Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid
More informationDAVID C. KOSEGARTEN, PH.D., R.PH.
MASTERING PHARMACY UCEIMSURE & CERTIFICATION A CASE-RASED REVIEW DAVID C. KOSEGARTEN, PH.D., R.PH. Associate Professor of Pharmacology and Toxicology Massachusetts College of Pharmacy and Health Sciences
More informationNotice from the Executive Officer: Promoting Compliance with the Existing Limited Use Criteria for Fentanyl Transdermal Patch
Notice from the Executive Officer: Promoting Compliance with the Existing Limited Use Criteria for Fentanyl Transdermal Patch Frequently Asked Questions 1. What is the new Health Network System feature
More informationMyalept. Myalept (metreleptin) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.45 Subject: Myalept Page: 1 of 5 Last Review Date: September 15, 2016 Myalept Description Myalept
More information15 mg morphine 10 mg hydrocodone
Cari untuk: Cari Cari 15 mg morphine 10 mg hydrocodone 3-2-2013 Convert From CALCULATED MORPHINE EQUIVALENT BY RESOURCE: Average ( mg ) Range ( mg ) Standard Deviation of Sample ( mg ) Hydrocodone. I usually
More informationDrug Utilization Review & Cost Reduction Strategies. Esther Liu, PharmD, MSIA, CGP Clinical Pharmacist Outcome Resources
Drug Utilization Review & Cost Reduction Strategies Esther Liu, PharmD, MSIA, CGP Clinical Pharmacist Outcome Resources Goals and Objectives Define Drug Utilization Reviews Interpret various performance
More informationFor patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.
Bedfordshire Palliative Care Palliative Care Medicines Guidance This folder has been produced to support professionals providing palliative care in any setting. Its aim is to make best practice in palliative
More informationMARYLAND MEDICAL ASSISTANCE PROGRAM Pharmacy Transmittal No Maryland Pharmacy Assistance Program Transmittal No. 39 February 22, 1999
1 PT17-99 MARYLAND MEDICAL ASSISTANCE PROGRAM Pharmacy Transmittal No. 160 Maryland Pharmacy Assistance Program Transmittal No. 39 February 22, 1999 TO: FROM: NOTE: RE: Physicians Pharmacists Martin P.
More informationSpring Understanding the potential of generic substitution
Spring 2014 Understanding the potential of generic substitution Understanding the potential of generic substitution Generic pricing reforms and the availability of generics for blockbuster drugs coming
More informationRequirements for the prescribing of Schedule 4 and Schedule 8 Medicines in Western Australia
Requirements for the prescribing of Schedule 4 and Schedule 8 Medicines in Western Australia Pharmaceutical Services Branch June 2008 1 Key Points Prescribing Schedule 4 medicines (S4s) S4 prescriptions
More informationDocument ref. no: Trust Policy and Procedure. PP(16)234 Prescribing, Dispensing and Administration of Methotrexate Policy
Document ref. no: Trust Policy and Procedure PP(16)234 Prescribing, Dispensing and Administration of Methotrexate Policy For use in: For use by: For use for: Document owner: Status: All Clinical Areas
More informationHigh-Alert Medications: A Look at the Safe Use of Narcotics. Allen Vaida, BSc, PharmD Institute for Safe Medication Practices (ISMP)
High-Alert Medications: A Look at the Safe Use of Narcotics Allen Vaida, BSc, PharmD Institute for Safe Medication Practices (ISMP) Risk Identification in Healthcare The detection of a potential or actual
More informationMedicare Part D Prescription Opioid Policies for 2019 Information for Pharmacists
CENTERS FOR MEDICARE & MEDICAID SERVICES Medicare Part D Prescription Opioid Policies for 2019 Information for Pharmacists Background Opioid medications are effective at treating certain types of pain,
More informationNews & Views. Antipsychotics on Maryland Medicaid PDL and Coverage of a 30-day Emergency Supply of Atypical Antipsychotics
Maryland Medicaid Pharmacy Program News & Views February 2011 Maryland Department of Health and Mental Hygiene /Office of Systems, Operations and Pharmacy Antipsychotics on Maryland Medicaid PDL and Coverage
More information